Ligand Pharma (LGND) Provides Updates at Analyst Day; Roth Capital Raises Price Target to $144
Tweet Send to a Friend
Roth Capital reiterated a Buy rating on Ligand Pharma (NASDAQ: LGND), and raised the price target to $144.00 (from $138.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
